Abstract 19234: IGF2 is a Modulator of Newborn's Fetal Growth and Adiposity.
Background: Obesity is a risk factor for coronary heart disease and may be partly of fetal origin. Having a small or large for gestational age newborn's weight was previously shown to be a predictor of future obesity and cardiovascular diseases in adult's life. Insulin growth factor 2 (IGF2) is a powerful intrauterine growth factor implicated in the regulation of growth hormone, insulin action, as well as a modulator of muscle growth and cell differentiation.
Objective: To demonstrate that IGF2 expression and placental DNA methylation at IGF2/H19 imprinted locus are correlated with maternal and newborn anthropometrics’ values.
Subjects and methods: Placenta tissues and maternal and cord blood samples were obtained from 48 women including 23 with gestational diabetes mellitus. Anthropometric parameters, blood pressure and metabolic phenotypes were measured using standardized procedures. IGF2 DNA methylation and circulating levels were assessed using sodium bisulfite pyrosequencing and ELISA respectively. Correlations were tested using Spearman rank correlation coefficients.
Results: We have observed significant correlations (p<0.05) between maternal lean body and fat masses at 12-14 weeks of gestation and concentrations of IGF2 at the end of the pregnancy (rs=0.40 and -0.40, respectively). Maternal IGF2 levels were correlated with total weight gain during pregnancy, as well as with maternal insulin concentration at 36-37 weeks of gestation (p<0.05; rs=0.37 and 0.56, respectively). Cord blood IGF2 levels and placental IGF2 DMR2 DNA methylation were correlated with newborn's height (rs=0.42 and 0.41), weight (rs=0.26 and 0.44) and placental weight (rs=0.27 and 0.26). No association was observed with maternal diabetic status or glycemic control or prenatal maternal body mass index.
Conclusion: This study suggest, prospectively, an interaction between prenatal maternal anthropometric characteristics during pregnancy and concentrations of IGF2. IGF2, as a modulator of newborn's fetal growth and adiposity could represent a cornerstone in fetal programming of late onset obesity and its cardiovascular complications.
- © 2010 by American Heart Association, Inc.